查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401940

2030 年血漿分餾市場預測：按產品、方法、應用、最終用戶和地區進行的全球分析

Plasma Fractionation Market Forecasts to 2030 - Global Analysis By Product (Immunoglobulins, Albumin, Platelets & Coagulation Factor Concentrates, Protease Inhibitors and Other Products), Method, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球血漿分餾市場規模將達到 290 億美元，預計到 2030 年將達到 462 億美元，預測期內複合年成長率為 6.9%。

為了創造可用於治療各種醫療狀況的治療產品，血漿的組成部分透過稱為血漿分餾的過程進行分離。血液的液體部分稱為血漿，含有蛋白質和身體運作所需的其他物質。血漿分餾分離和精製這些蛋白質用於醫療用途。血漿分餾是一種重要的手術，可為多種疾病提供挽救生命的治療方法。然而，必須嚴格遵守品質和安全要求，以確保成品無害、高效、無雜質。

根據 Springer 2022 年 1 月發表的一項研究，獲得性A型血友病(AHA) 是一種罕見、嚴重的後天性出血性疾病，每年每百萬人中僅影響 1 至 150 人。

免疫不全症增加

在全球範圍內，對血漿生產的治療藥物的需求顯著增加。對免疫球蛋白的強勁需求促進了全球市場的強勁擴張。需求的增加是由於全球各種免疫力缺乏疾病的增加。免疫球蛋白替代療法或標靶免疫球蛋白療法是這些疾病的兩種可能的治療方法。因此，隨著對這些治療方法的需求增加，透過這些方法產生的免疫球蛋白的量也增加，從而推動市場。

基因編輯療法的出現

透過特異性針對基因缺陷，基因編輯療法提供了疾病治療的新方法，並可能最終消除對血漿衍生療法的需求。由於對血漿生產的產品的需求減少，基因編輯療法的使用可能會導致血漿分餾公司的市場佔有率和收入下降。如果治療模式顯著轉向基因編輯，嚴重依賴血漿衍生療法的公司可能會受到財務影響，從而抑制市場。

世界各地有更多血漿採集設施

血漿（血漿血漿分餾的原料）供應的增加可能會導致收集設施的增加。血漿可用性的增加可能對生產血漿衍生產品（如白蛋白、凝血因子和免疫球蛋白）的能力產生有益影響。血漿分餾市場可能受到血漿採集設施的位置和法律體制的影響。此外，各國關於安全要求、血漿採集以及血漿衍生產品進出口的規定也各不相同。

技術挑戰

過時或低效的血漿分餾方法等技術問題可能會增加處理時間並降低生產率。這些低效率可能導致血漿衍生產品的產量降低，限制了可分配的數量並增加了成本。一些過時的技術和流程可能會造成可擴展性問題，從而難以提高生產水準以滿足需求。可擴展性不足可能會阻礙市場成長並導致供不應求。

COVID-19 的影響

由於 COVID-19，對血漿產品（尤其是免疫球蛋白）的需求激增。對於嚴重COVID-19 患者，這些抗體被認為是一種治療選擇。因此，對來自 COVID-19 倖存者的血漿的需求不斷增加，以製造恢復期血漿和含有超免疫球蛋白的治療方法。為了應對大流行帶來的挑戰，監管機構改變了規則和法規，以確保血漿衍生產品的安全性和可得性。

免疫球蛋白部分預計將成為預測期內最大的部分

由於免疫球蛋白用於治療各種疾病，如免疫力缺乏、自體免疫疾病和一些神經系統疾病，預計免疫球蛋白領域將出現良好的成長。靜脈注射免疫球蛋白（IVIG）是從血漿分餾中獲得的物質，廣泛用於治療各種疾病和增強免疫系統。透過血漿分餾程序的持續技術改進，提高了產品產量和質量，從而增強了分離免疫球蛋白和其他血漿蛋白的有效性。

深層過濾領域預計在預測期內複合年成長率最高

由於深度過濾是免疫球蛋白和其他重要成分等蛋白質精製和分離的關鍵步驟，因此預計深度過濾領域在預測期內將以最高複合年成長率成長。深度過濾是去除污染物、獲得高純度蛋白質產品的關鍵技術之一。這個過程取決於過濾基質的深度，因為它捕獲並保留不同尺寸的顆粒，並根據其尺寸、型態以及與過濾材料的相互作用將它們與所需成分分離。

佔有率最大的地區：

預計亞太地區在預測期內將佔據最大的市場佔有率。這是因為政府當局監督和控制血漿收集、分離和銷售是推動市場成長的關鍵因素，因此，亞太地區是血漿分餾產業的重要參與企業，提供了有利的可能性。此外，專注於開拓亞太地區新興市場以獲取更大市場佔有率的頂級製造商的激增預計將推動血漿分餾行業的成長。

複合年成長率最高的地區：

預計北美在預測期內的複合年成長率最高，並且由於主要企業的存在、血漿分餾人口高齡化，預計將佔據血漿分餾市場的很大一部分。此外，該地區血漿採集設施的擴建以及提高血漿供應量的持續努力預計將推動市場擴張。例如，Grifols SA 和加拿大血液服務中心 (CBS) 於 2022 年 9 月加入，以增加加拿大的全國血漿供應。因此，老年人口的增加、醫療保健支出的增加以及關鍵市場的舉措不斷增加正在推動市場成長。

免費客製化服務：

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球血漿分餾市場：依產品

  • 介紹
  • 免疫球蛋白
    • 皮下注射免疫球蛋白
    • 靜脈注射免疫球蛋白
  • 白蛋白
  • 血小板和凝血因子濃縮物
    • 因子VIII
    • 因子IX
    • 血管性血友病因子
    • 纖維蛋白原濃縮物
    • 凝血酶原複合物濃縮物
    • 因子XIII
    • 其他濃縮血小板和凝血因子
  • 蛋白酶抑制劑
  • 其他產品

第6章全球血漿分餾市場：依方法

  • 介紹
  • 深層過濾
  • 層析法
  • 離心

第7章全球血漿分餾市場：依應用分類

  • 介紹
  • 免疫學
  • 神經病學
  • 重症監護
  • 血液學
  • 風濕病學
  • 血液腫瘤學
  • 呼吸系統醫療設備
  • 其他用途

第8章全球血漿分餾市場：依最終用戶分類

  • 介紹
  • 臨床研究所
  • 醫院和診所
  • 學術機構
  • 其他最終用戶

第9章全球血漿分餾市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Grifols, SA
  • Intas Pharmaceuticals Ltd.
  • LFB
  • Takeda Pharmaceutical company limited
  • Octapharma AG
  • Sanquin
  • Emergent BioSolutions
  • Shanghai Raas Blood Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Kamada
  • Centurion Pharma
  • Virchow Biotech Private Limited
  • Fusion Healthcare
  • Hemarus Therapeutics Limited
  • Hualan Bioengineering Co., Ltd.
  • China Biologic Products Holdings Inc.
  • ADMA Biologics
  • CSL
  • Baxter International Inc
  • Bio Products Laboratory
Product Code: SMRC24460

According to Stratistics MRC, the Global Plasma Fractionation Market is accounted for $29.0 billion in 2023 and is expected to reach $46.2 billion by 2030 growing at a CAGR of 6.9% during the forecast period. In order to create therapeutic products that can be utilized to treat a variety of medical diseases, blood plasma's constituent parts are separated through a procedure called plasma fractionation. The liquid portion of blood, known as blood plasma, includes proteins and other materials necessary for body operations. These proteins are separated and purified for use in medicine using plasma fractionation. A vital procedure that offers treatments that can save lives for a variety of illnesses is plasma fractionation. Nonetheless, to guarantee that the finished goods are risk-free, efficient, and devoid of impurities, stringent adherence to quality and safety requirements is necessary.

According to a research study published by Springer in January 2022, Acquired hemophilia A (AHA) is a severe acquired rare bleeding disorder with which only 1-1.5 per million persons are affected yearly.

Market Dynamics:

Driver:

Increasing numbers of immunodeficiency disorders

Worldwide, there has been a noticeable increase in the demand for treatments produced from plasma. Strong demand for immunoglobulin contributed to the global market's good expansion. The increase in different immunodeficiency diseases instances worldwide is the cause of the increased demand. Immunoglobulin replacement or targeted immunoglobulin therapy are two possible treatments for these illnesses. Consequently, as the need for these therapies grows, so does the amount of immunoglobulin produced by these methods, which propels the market.

Restraint:

Emergence of gene-editing therapies

By specifically targeting genetic defects, gene-editing therapies provide novel approaches to treating diseases and may eventually eliminate the need for some plasma-derived therapies. The use of gene-editing therapies may lead to a drop in the market share and income for plasma fractionation companies as a result of a decrease in the demand for products produced from plasma. Businesses that depend significantly on plasma-derived treatments may face financial consequences in the event that treatment paradigms significantly shift in favour of gene editing thereby hampering the market.

Opportunity:

Rise in plasma collection facilities across the globe

An increased supply of plasma as the raw material for plasma fractionation could result from more collection facilities. This increase in plasma availability may have a beneficial effect on the ability to produce products derived from plasma, such as albumin, clotting factors, and immunoglobulins. The market for plasma fractionation may be impacted by the location and legal framework of plasma collection facilities. Moreover, regulations pertaining to safety requirements, plasma collection, and the import and export of goods obtained from plasma vary throughout nations.

Threat:

Technological challenges

Problems with technology, like antiquated or ineffective plasma fractionation methods, can cause processing times to increase and productivity to decrease. Lower yields of plasma-derived products could be the consequence of this inefficiency, which would restrict the amount available for distribution and possibly raise expenses. Scalability issues may arise with some outdated technology or processes, making it challenging to raise output levels to keep up with demand. Inadequate scalability can impede the growth of markets and cause shortages in supplies.

COVID-19 Impact

The demand for goods produced from plasma, especially immunoglobulins, surged as a result of COVID-19. For COVID-19 patients who are extremely sick, these antibodies were investigated as a possible therapy option. As a result, there was an increase in the need for plasma from COVID-19 survivors in order to create convalescent plasma and maybe create treatments involving hyper immune globulin. To handle issues brought on by the pandemic, regulatory bodies modified their rules and regulations, guaranteeing the security and availability of goods obtained from plasma.

The immunoglobulins segment is expected to be the largest during the forecast period

The immunoglobulins segment is estimated to have a lucrative growth, as immunoglobulins are used to treat a range of illnesses, such as immune deficiencies, autoimmune disorders, and several neurological ailments. Intravenous immunoglobulin (IVIG) is a widely used substance that is derived from plasma fractionation and is used to treat a variety of illnesses and strengthen the immune system. The effectiveness of isolating immunoglobulins and other plasma proteins has been enhanced by ongoing technological improvements in plasma fractionation procedures, improving product yields and quality.

The depth filtration segment is expected to have the highest CAGR during the forecast period

The depth filtration segment is anticipated to witness the highest CAGR growth during the forecast period, because depth filtration is a crucial step in the purification and separation of proteins, including immunoglobulins and other vital constituents. It is used as one of the main techniques to get high-purity protein products by eliminating contaminants. In order to capture and hold particles of different sizes and separate them from the required components according to their size, shape, and interaction with the filter material, this procedure depends on the depth of the filter matrix thus boosting the market.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period, owing to the presence of governmental authorities that oversee and control plasma collection, fractionation, and sales is a major element driving the market's growth, and as a result, Asia-Pacific offers important participants in the plasma fractionation industry lucrative potential. Furthermore, a sharp increase in the emphasis of top producers on regional expansion in developing Asia-Pacific nations in order to gain a larger market share is anticipated to propel the growth of the plasma fractionation industry.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the presence of key companies, growing research and development efforts related to plasma fractionation, and an aging population, the North American region is anticipated to occupy a sizable proportion of the market for plasma fractionation. Furthermore, the expansion of plasma collecting facilities in the area as well as ongoing initiatives to increase the availability of plasma is anticipated to fuel market expansion. For example, in order to increase Canada's national blood plasma supply, Grifols SA and Canadian Blood Services (CBS) joined in September 2022. Thus the growing geriatric population, rising healthcare spending, and rising initiatives from key market are propelling the market growth.

Key players in the market:

Some of the key players profiled in the Plasma Fractionation Market include Grifols, S.A., Intas Pharmaceuticals Ltd., LFB, Takeda Pharmaceutical company limited, Octapharma AG, Sanquin, Emergent BioSolutions, Shanghai Raas Blood Products Co., Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Kamada, Centurion Pharma, Virchow Biotech Private Limited, Fusion Healthcare, Hemarus Therapeutics Limited, Hualan Bioengineering Co., Ltd., China Biologic Products Holdings Inc., ADMA Biologics, CSL, Baxter International Inc and Bio Products Laboratory

Key Developments:

In December 2023, Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate. This current version of Emergent's universal influenza vaccine candidate contains multiple components intended to induce broad.

In October 2023, Baxter Launches Digital Image Capture Capability for PanOptic Plus Ophthalmoscope, the iExaminer Pro System adds a key technology to routine eye exams, designed.

In July 2023, Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S. The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to Kedrion in 2022 and Anticipates a Significant Increase in 2023

Products Covered:

  • Immunoglobulins
  • Albumin
  • Platelets & Coagulation Factor Concentrates
  • Protease Inhibitors
  • Other Products

Methods Covered:

  • Depth Filtration
  • Chromatography
  • Centrifugation

Applications Covered:

  • Immunology
  • Neurology
  • Critical Care
  • Hematology
  • Rheumatology
  • Hemato-Oncology
  • Pulmonology
  • Other Applications

End Users Covered:

  • Clinical Research Laboratories
  • Hospitals & Clinics
  • Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Plasma Fractionation Market, By Product

  • 5.1 Introduction
  • 5.2 Immunoglobulins
    • 5.2.1 Subcutaneous Immunoglobulin
    • 5.2.2 Intravenous Immunoglobulin
  • 5.3 Albumin
  • 5.4 Platelets & Coagulation Factor Concentrates
    • 5.4.1 Factor VIII
    • 5.4.2 Factor IX
    • 5.4.3 Von Willebrand Factor
    • 5.4.4 Fibrinogen Concentrates
    • 5.4.5 Prothrombin Complex Concentrates
    • 5.4.6 Factor XIII
    • 5.4.7 Other Platelets & Coagulation Factor Concentrates
  • 5.5 Protease Inhibitors
  • 5.6 Other Products

6 Global Plasma Fractionation Market, By Method

  • 6.1 Introduction
  • 6.2 Depth Filtration
  • 6.3 Chromatography
  • 6.4 Centrifugation

7 Global Plasma Fractionation Market, By Application

  • 7.1 Introduction
  • 7.2 Immunology
  • 7.3 Neurology
  • 7.4 Critical Care
  • 7.5 Hematology
  • 7.6 Rheumatology
  • 7.7 Hemato-Oncology
  • 7.8 Pulmonology
  • 7.9 Other Applications

8 Global Plasma Fractionation Market, By End User

  • 8.1 Introduction
  • 8.2 Clinical Research Laboratories
  • 8.3 Hospitals & Clinics
  • 8.4 Academic Institutes
  • 8.5 Other End Users

9 Global Plasma Fractionation Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Grifols, S.A.
  • 11.2 Intas Pharmaceuticals Ltd.
  • 11.3 LFB
  • 11.4 Takeda Pharmaceutical company limited
  • 11.5 Octapharma AG
  • 11.6 Sanquin
  • 11.7 Emergent BioSolutions
  • 11.8 Shanghai Raas Blood Products Co., Ltd.
  • 11.9 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • 11.10 Kamada
  • 11.11 Centurion Pharma
  • 11.12 Virchow Biotech Private Limited
  • 11.13 Fusion Healthcare
  • 11.14 Hemarus Therapeutics Limited
  • 11.15 Hualan Bioengineering Co., Ltd.
  • 11.16 China Biologic Products Holdings Inc.
  • 11.17 ADMA Biologics
  • 11.18 CSL
  • 11.19 Baxter International Inc
  • 11.20 Bio Products Laboratory

List of Tables

  • Table 1 Global Plasma Fractionation Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Plasma Fractionation Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Plasma Fractionation Market Outlook, By Immunoglobulins (2021-2030) ($MN)
  • Table 4 Global Plasma Fractionation Market Outlook, By Subcutaneous Immunoglobulin (2021-2030) ($MN)
  • Table 5 Global Plasma Fractionation Market Outlook, By Intravenous Immunoglobulin (2021-2030) ($MN)
  • Table 6 Global Plasma Fractionation Market Outlook, By Albumin (2021-2030) ($MN)
  • Table 7 Global Plasma Fractionation Market Outlook, By Platelets & Coagulation Factor Concentrates (2021-2030) ($MN)
  • Table 8 Global Plasma Fractionation Market Outlook, By Factor VIII (2021-2030) ($MN)
  • Table 9 Global Plasma Fractionation Market Outlook, By Factor IX (2021-2030) ($MN)
  • Table 10 Global Plasma Fractionation Market Outlook, By Von Willebrand Factor (2021-2030) ($MN)
  • Table 11 Global Plasma Fractionation Market Outlook, By Fibrinogen Concentrates (2021-2030) ($MN)
  • Table 12 Global Plasma Fractionation Market Outlook, By Prothrombin Complex Concentrates (2021-2030) ($MN)
  • Table 13 Global Plasma Fractionation Market Outlook, By Factor XIII (2021-2030) ($MN)
  • Table 14 Global Plasma Fractionation Market Outlook, By Other Platelets & Coagulation Factor Concentrates (2021-2030) ($MN)
  • Table 15 Global Plasma Fractionation Market Outlook, By Protease Inhibitors (2021-2030) ($MN)
  • Table 16 Global Plasma Fractionation Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 17 Global Plasma Fractionation Market Outlook, By Method (2021-2030) ($MN)
  • Table 18 Global Plasma Fractionation Market Outlook, By Depth Filtration (2021-2030) ($MN)
  • Table 19 Global Plasma Fractionation Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 20 Global Plasma Fractionation Market Outlook, By Centrifugation (2021-2030) ($MN)
  • Table 21 Global Plasma Fractionation Market Outlook, By Application (2021-2030) ($MN)
  • Table 22 Global Plasma Fractionation Market Outlook, By Immunology (2021-2030) ($MN)
  • Table 23 Global Plasma Fractionation Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 24 Global Plasma Fractionation Market Outlook, By Critical Care (2021-2030) ($MN)
  • Table 25 Global Plasma Fractionation Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 26 Global Plasma Fractionation Market Outlook, By Rheumatology (2021-2030) ($MN)
  • Table 27 Global Plasma Fractionation Market Outlook, By Hemato-Oncology (2021-2030) ($MN)
  • Table 28 Global Plasma Fractionation Market Outlook, By Pulmonology (2021-2030) ($MN)
  • Table 29 Global Plasma Fractionation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 30 Global Plasma Fractionation Market Outlook, By End User (2021-2030) ($MN)
  • Table 31 Global Plasma Fractionation Market Outlook, By Clinical Research Laboratories (2021-2030) ($MN)
  • Table 32 Global Plasma Fractionation Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 33 Global Plasma Fractionation Market Outlook, By Academic Institutes (2021-2030) ($MN)
  • Table 34 Global Plasma Fractionation Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.